MX2024007015A - Inhibidor de cdk4 y 6 en combinacion con fulvestrant para el tratamiento del cancer de mama avanzado o metastasico con receptor hormonal positivo y receptor 2 del factor de crecimiento epidermico humano negativo en pacientes tratados anteriormente con un inhibidor de cdk4 y 6. - Google Patents
Inhibidor de cdk4 y 6 en combinacion con fulvestrant para el tratamiento del cancer de mama avanzado o metastasico con receptor hormonal positivo y receptor 2 del factor de crecimiento epidermico humano negativo en pacientes tratados anteriormente con un inhibidor de cdk4 y 6.Info
- Publication number
- MX2024007015A MX2024007015A MX2024007015A MX2024007015A MX2024007015A MX 2024007015 A MX2024007015 A MX 2024007015A MX 2024007015 A MX2024007015 A MX 2024007015A MX 2024007015 A MX2024007015 A MX 2024007015A MX 2024007015 A MX2024007015 A MX 2024007015A
- Authority
- MX
- Mexico
- Prior art keywords
- cdk4
- inhibitor
- fulvestrant
- advanced
- negative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163288179P | 2021-12-10 | 2021-12-10 | |
| US202263321218P | 2022-03-18 | 2022-03-18 | |
| PCT/US2022/052071 WO2023107525A1 (en) | 2021-12-10 | 2022-12-07 | Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024007015A true MX2024007015A (es) | 2024-06-19 |
Family
ID=85157124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007015A MX2024007015A (es) | 2021-12-10 | 2022-12-07 | Inhibidor de cdk4 y 6 en combinacion con fulvestrant para el tratamiento del cancer de mama avanzado o metastasico con receptor hormonal positivo y receptor 2 del factor de crecimiento epidermico humano negativo en pacientes tratados anteriormente con un inhibidor de cdk4 y 6. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240398832A1 (https=) |
| EP (1) | EP4444315A1 (https=) |
| JP (1) | JP2023086719A (https=) |
| KR (1) | KR20240118134A (https=) |
| AU (1) | AU2022408062B2 (https=) |
| CA (1) | CA3240454A1 (https=) |
| IL (1) | IL313422A (https=) |
| MX (1) | MX2024007015A (https=) |
| TW (1) | TW202342044A (https=) |
| WO (1) | WO2023107525A1 (https=) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2251677T3 (es) | 2002-01-22 | 2006-05-01 | Warner-Lambert Company Llc | 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas. |
| ATE412650T1 (de) | 2003-07-11 | 2008-11-15 | Warner Lambert Co | Isethionat salz eines selektiven cdk4 inhibitors |
| BRPI0716880A2 (pt) | 2006-09-08 | 2013-10-15 | Pfizer Prod Inc | Síntese de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas |
| JO2885B1 (en) | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
| AR083797A1 (es) | 2010-11-10 | 2013-03-20 | Novartis Ag | Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos |
| SI2958916T1 (sl) | 2013-02-21 | 2018-11-30 | Pfizer Inc. | Trdne oblike selektivnih zaviralcev CDK4/6 |
| KR20180119570A (ko) * | 2016-03-15 | 2018-11-02 | 메리맥 파마슈티컬즈, 인크. | 항-ErbB3 항체를 포함하는 병용 요법을 이용한 ER+, HER2-, HRG+ 유방암의 치료 |
| CN115624552A (zh) | 2017-05-02 | 2023-01-20 | 伊莱利利公司 | 用于乳腺癌的辅助治疗的内分泌疗法和abemaciclib组合 |
| WO2021030248A1 (en) * | 2019-08-12 | 2021-02-18 | Genentech, Inc. | Treatment of breast cancer using combination therapies comprising an atp competitive akt inhibitor, a cdk4/6 inhibitor, and fulvestrant |
-
2022
- 2022-12-07 CA CA3240454A patent/CA3240454A1/en active Pending
- 2022-12-07 IL IL313422A patent/IL313422A/en unknown
- 2022-12-07 US US18/717,475 patent/US20240398832A1/en active Pending
- 2022-12-07 AU AU2022408062A patent/AU2022408062B2/en active Active
- 2022-12-07 EP EP22851077.2A patent/EP4444315A1/en active Pending
- 2022-12-07 WO PCT/US2022/052071 patent/WO2023107525A1/en not_active Ceased
- 2022-12-07 MX MX2024007015A patent/MX2024007015A/es unknown
- 2022-12-07 KR KR1020247022368A patent/KR20240118134A/ko active Pending
- 2022-12-09 TW TW111147357A patent/TW202342044A/zh unknown
- 2022-12-09 JP JP2022197331A patent/JP2023086719A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240398832A1 (en) | 2024-12-05 |
| AU2022408062B2 (en) | 2025-08-14 |
| CA3240454A1 (en) | 2023-06-15 |
| WO2023107525A1 (en) | 2023-06-15 |
| TW202342044A (zh) | 2023-11-01 |
| IL313422A (en) | 2024-08-01 |
| EP4444315A1 (en) | 2024-10-16 |
| AU2022408062A1 (en) | 2024-06-20 |
| KR20240118134A (ko) | 2024-08-02 |
| JP2023086719A (ja) | 2023-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022010270A (es) | Nuevo enfoque para tratar el cancer mediante el uso de la inmunomodulacion. | |
| CR20190376A (es) | Formulaciones de anticuerpos de her2 subcutáneas | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| PH12021551023A1 (en) | Methods for shrinking pituitary tumors | |
| MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
| MX2020008395A (es) | Osimertinib para su uso en el tratamiento de cáncer de pulmón de células no pequeñas. | |
| MX2021000726A (es) | Terapia combinada de gen de activacion de linfocitos 3(lag-3) para el tratamiento del cancer. | |
| Hwang et al. | Clinical effectiveness of complex decongestive physiotherapy for malignant lymphedema: a pilot study | |
| EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| MX2020012540A (es) | Uso de inhibidor de cdk4/6 en combinacion con inhibidor del egfr en la preparacion de medicamento para tratar enfermedades tumorales. | |
| MX2022006566A (es) | Tratamientos conjuntos para tratamiento de cancer de mama. | |
| PH12022553333A1 (en) | Markers for use in methods for treating cancers with antibody drug conjugates (adc) | |
| MX390755B (es) | Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento. | |
| MX2025004433A (es) | Combinaciones de un degradador selectivo del receptor de estrogenos (serd) para el tratamiento del cancer | |
| PH12021551805A1 (en) | Treatment of skin lesions and pruritus in prurigo nodularis patients | |
| CL2019000846A1 (es) | Proteína terapéutica. | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
| MX2024005220A (es) | Endoxifeno para el tratamiento del cancer. | |
| MX2024007015A (es) | Inhibidor de cdk4 y 6 en combinacion con fulvestrant para el tratamiento del cancer de mama avanzado o metastasico con receptor hormonal positivo y receptor 2 del factor de crecimiento epidermico humano negativo en pacientes tratados anteriormente con un inhibidor de cdk4 y 6. | |
| MX2021003160A (es) | Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama. | |
| MX2021001764A (es) | Terapia de combinacion. | |
| MX2024003563A (es) | Composicion farmaceutica combinada de inhibidor de cdk4/6 e inhibidor de aromatasa. | |
| CL2019001262A1 (es) | Métodos para tratar las carcinomas uroteliales del tracto superior. | |
| BR112022018238A2 (pt) | Método de tratamento de um câncer em um sujeito | |
| PH12021550417A1 (en) | Compositions and methods for controlled ovarian stimulation |